胃癌术后单纯化疗与放化疗联合治疗随机对照试验的Meta分析
发布时间：2018-10-17 11:42
【摘要】：目的：采用循证医学Meta分析的方法分析胃癌术后放化疗联合与单纯化疗的随机对照试验的结果差异,‘评价其有效性及安全性。方法：检索相关期刊论文(CNKI)、维普数据库(VIP)、中国生物医学文献数据库(CBM); Cochrane图书馆、PubMed和EMBASE(检索截至日期为2014年6月),纳入有关胃癌术后放疗联合化疗及单纯化疗的随机对照试验(RCT),并对所纳入的文献进行质量评价,收集文献内数据,采用RevMan5.2和Stata 12.0软件进行分析评价。比较两组1、2、3年生存率；3、5年疾病无进展生存期(PFS),5年总生存率(OS),以及治疗出现的中重度胃肠道反应,骨髓抑制,手足综合征等不良反应指标。结果：最终纳入11个RCT,共包括1143例患者,均为术后放化疗联合与单纯化疗的随机对照试验。Meta分析结果显示：1.进展期胃癌术后放化疗联合较之单纯化疗1年生存率[RR=1.20(95%CI：1.10～1.30)]、2年生存率[RR=1.34(95%CI:1.16～1.56)]、3年生存率[RR=1.57(95%CI：1.27-1.86)]、3年疾病无进展生存率[RR=1.10(95%CI：1.00～1.21)],5年疾病无进展生存率[RR=1.27(95%CI:1.02～1.60)]及5年总生存率[RR=1.24(95%CI：1.01～1.51)]差异均存在统计学意义,对胃癌D2淋巴结清扫术后进行亚组分析,在生存期差异与整体相似；2.两组在Ⅲ-Ⅳ度白细胞减低发生[RR=1.24(95%CI：1.02-1.50)]差异存在统计学意义,但在其他不良反应中如：Ⅲ-Ⅳ血红蛋白减低,血小板减低,胃肠道反应,手足综合征等发生率相似,差异并没有统计学意义。结论：胃癌术后放化疗联合辅助治疗较之单纯化疗在提高胃癌患者的生存时间获益更为明显,且与放化疗相关的不良反应未明显增加,患者耐受依存性尚可。
[Abstract]:Objective: to evaluate the efficacy and safety of radiotherapy and chemotherapy combined with chemotherapy alone in patients with gastric cancer. Methods: the (CBM); Cochrane library, PubMed and EMBASE (search date is June 2014) of the Chinese Journal Full-text Database (CNKI),) and the Chinese Biomedical Literature Database (VIP),) were searched, which included radiotherapy combined with chemotherapy and simplex chemotherapy after operation for gastric cancer. Randomized controlled trial (RCT),) was conducted to evaluate the quality of the literature involved. The data were collected and evaluated by RevMan5.2 and Stata 12.0 software. The survival rate of 1 and 3 years, the 5 year overall survival rate of (PFS), for 3 and 5 years without progression of disease, and the adverse reactions such as moderate and severe gastrointestinal reaction, bone marrow suppression, hand and foot syndrome were compared between the two groups. Results: 1143 patients were included in 11 RCT, patients. All of them were randomized controlled trials of radiotherapy and chemotherapy combined with chemotherapy alone. The results of Meta analysis showed: 1. 1 year survival rate [RR=1.20 (95%CI:1.10~1.30)], 2 year survival rate [RR=1.34 (95%CI:1.16~1.56)], 3 year survival rate [RR=1.57 (95%CI:1.27-1.86)], 3 year progression free survival rate [RR=1.10 (95%CI:1.00~1.21)], 5 years disease progression free survival rate [RR=1.27 (95%CI:1.02~1.60)] and 5 The annual overall survival rate [RR=1.24 (95%CI:1.01~1.51)] was statistically significant. The subgroup analysis of D2 lymph node dissection of gastric cancer showed that the difference of survival time was similar to that of the whole. 2. The incidence of RR=1.24 (95%CI:1.02-1.50) in grade 鈪，
本文编号：2276547
[Abstract]:Objective: to evaluate the efficacy and safety of radiotherapy and chemotherapy combined with chemotherapy alone in patients with gastric cancer. Methods: the (CBM); Cochrane library, PubMed and EMBASE (search date is June 2014) of the Chinese Journal Full-text Database (CNKI),) and the Chinese Biomedical Literature Database (VIP),) were searched, which included radiotherapy combined with chemotherapy and simplex chemotherapy after operation for gastric cancer. Randomized controlled trial (RCT),) was conducted to evaluate the quality of the literature involved. The data were collected and evaluated by RevMan5.2 and Stata 12.0 software. The survival rate of 1 and 3 years, the 5 year overall survival rate of (PFS), for 3 and 5 years without progression of disease, and the adverse reactions such as moderate and severe gastrointestinal reaction, bone marrow suppression, hand and foot syndrome were compared between the two groups. Results: 1143 patients were included in 11 RCT, patients. All of them were randomized controlled trials of radiotherapy and chemotherapy combined with chemotherapy alone. The results of Meta analysis showed: 1. 1 year survival rate [RR=1.20 (95%CI:1.10~1.30)], 2 year survival rate [RR=1.34 (95%CI:1.16~1.56)], 3 year survival rate [RR=1.57 (95%CI:1.27-1.86)], 3 year progression free survival rate [RR=1.10 (95%CI:1.00~1.21)], 5 years disease progression free survival rate [RR=1.27 (95%CI:1.02~1.60)] and 5 The annual overall survival rate [RR=1.24 (95%CI:1.01~1.51)] was statistically significant. The subgroup analysis of D2 lymph node dissection of gastric cancer showed that the difference of survival time was similar to that of the whole. 2. The incidence of RR=1.24 (95%CI:1.02-1.50) in grade 鈪，
本文编号：2276547
本文链接：https://www.wllwen.com/yixuelunwen/zlx/2276547.html
